Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Trevi Therapeutics ( (TRVI) ) has issued an update.
On June 2, 2025, Trevi Therapeutics announced positive topline results from its Phase 2b CORAL clinical trial for Haduvio, showing significant reductions in 24-hour cough frequency in patients with idiopathic pulmonary fibrosis. The trial demonstrated statistically significant improvements in both primary and secondary endpoints, with a favorable safety profile. The company plans to meet with the FDA in the second half of 2025 to discuss a Phase 3 program and intends to initiate additional trials for chronic cough in non-IPF interstitial lung disease and refractory chronic cough in 2025 and 2026, respectively.
The most recent analyst rating on (TRVI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Trevi Therapeutics stock, see the TRVI Stock Forecast page.
Spark’s Take on TRVI Stock
According to Spark, TipRanks’ AI Analyst, TRVI is a Neutral.
Trevi Therapeutics shows promise with significant clinical progress and a strong cash position, essential for sustaining operations in a pre-revenue phase. However, ongoing financial losses and valuation risks temper the outlook. The stock’s technical indicators suggest strong momentum, but investors should be cautious due to potential volatility and financial risks inherent in early-stage biotechnology companies.
To see Spark’s full report on TRVI stock, click here.
More about Trevi Therapeutics
Trevi Therapeutics, Inc. is a pharmaceutical company focused on developing treatments for chronic cough and other conditions. Their primary product, Haduvio (oral nalbuphine ER), targets chronic cough in patients with idiopathic pulmonary fibrosis and potentially other lung diseases.
Average Trading Volume: 2,319,792
Technical Sentiment Signal: Buy
Current Market Cap: $662.4M
Find detailed analytics on TRVI stock on TipRanks’ Stock Analysis page.